Calmune and Crucell sign antibody research pact
This article was originally published in Scrip
Executive Summary
Calmune and Crucell have agreed a research collaboration that uses Calmune's technology platform to discover a slate of human monoclonal antibodies against a pre-defined, undisclosed infectious disease target.